A study of GR1803 for lupus
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This trial tests a new drug called GR1803 for people with systemic lupus erythematosus (SLE), an autoimmune disease that causes inflammation. It may help reduce disease activity when standard treatments haven't worked well enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of systemic lupus erythematosus (SLE).
- Your lupus disease activity score (SLEDAI-2K) must be 6 or higher, meaning moderate to severe symptoms.
- You must be able to understand and sign a consent form, and follow the study rules.
- You must have been on a stable dose of steroids, antimalarial drugs, or immunosuppressants for at least 3 months before joining.
- You cannot have unstable health conditions from other diseases or active infections.
- You cannot have had a cancerous tumor in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called ACE1831 for people with active systemic lupus erythematosus (lupus) whose disease has not improved with usual treatments. The goal is to see if ACE1831 can reduce lupus activity and help control symptoms.
This trial tests a new treatment called PRG-1801 for people with lupus nephritis (kidney inflammation from lupus) or IgG4-related disease that has not improved with standard treatments. The treatment uses your own immune cells to target and calm the disease.
This trial tests a new treatment, EVM18001, for people with lupus, myasthenia gravis, or systemic sclerosis that hasn't improved with standard therapies. It aims to see if this therapy can help control the disease.
This study tests a new injectable medicine (SG301) for people with lupus (SLE) whose current treatments are not working well enough or cause side effects. It aims to see if this targeted therapy can better control lupus symptoms.
This study tests a new injection called ACG102 for people with lupus that has not improved with standard treatments. The goal is to see if it can help control active lupus symptoms.
This trial tests an investigational injection called CM313 for people with active lupus (systemic lupus erythematosus). It aims to see if the drug can help reduce lupus symptoms and control the disease.
Hear when a new Systemic Lupus Erthematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.